Intervention Protocol

Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation

  1. Lise J Estcourt1,*,
  2. Richard Gregg2,
  3. Simon Stanworth1,
  4. Carolyn Doree3,
  5. Marialena Trivella4,
  6. Michael F Murphy5,
  7. Alan Tinmouth6

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 19 MAR 2014

DOI: 10.1002/14651858.CD010982


How to Cite

Estcourt LJ, Gregg R, Stanworth S, Doree C, Trivella M, Murphy MF, Tinmouth A. Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 3. Art. No.: CD010982. DOI: 10.1002/14651858.CD010982.

Author Information

  1. 1

    NHS Blood and Transplant, Haematology/Transfusion Medicine, Oxford, UK

  2. 2

    University Hospitals Birmingham NHS Foundation Trust, Department of Haematology, Birmingham, UK

  3. 3

    NHS Blood and Transplant, Systematic Review Initiative, Oxford, UK

  4. 4

    University of Oxford, Centre for Statistics in Medicine, Oxford, UK

  5. 5

    John Radcliffe Hospital, NHS Blood and Transplant, Oxford, UK

  6. 6

    The Ottawa Health Research Institute and the University of Ottawa, Medicine (hematology) and Pathology Centre for Transfusion Research, Ottawa, Ontario, Canada

*Lise J Estcourt, Haematology/Transfusion Medicine, NHS Blood and Transplant, Level 2, John Radcliffe Hospital, Headington, Oxford, OX3 9BQ, UK. lise.estcourt@nhsbt.nhs.uk. lestcourt@doctors.org.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 19 MAR 2014

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To determine whether alternative agents (e.g. artificial platelet substitutes, platelet-poor plasma, fibrinogen, rFVIIa, thrombopoietin mimetics) are as effective and safe as the use of platelet transfusions for the prevention of bleeding (prophylactic platelet transfusion) in patients with haematological disorders who are undergoing myelosuppressive chemotherapy or stem cell transplantation. Anti-fibrinolytics (lysine analogues) will not be included in this review because they have been the focus of another Cochrane review (Wardrop 2013).